Takis

What Takis does

Takis S.r.l. is an Italian biotechnology company founded around 2010 and headquartered at the Tecnopolo di Castel Romano in Rome, operating in immunotherapy, monoclonal antibody generation, recombinant protein production, DNA vaccine development, and gene therapy. The company's core technological assets include a proprietary DNA electroporation-based immunization platform for generating high-affinity monoclonal antibodies without requiring antigen protein expression, the X-eVax thermostable synthetic DNA vaccine platform (eliminating cold-chain logistics), a microfluidic B-cell isolation and characterization system, and a Protein Production Facility (PPF) supporting expression in E. coli, insect cells (Sf21/High-Five), and mammalian systems (CHO/293F). Integrated infrastructure includes a BSL-3 laboratory, a GMP facility, and the newly constructed Rome GeneHub complex for nucleic acid and monoclonal antibody manufacturing.

The business operates a hybrid revenue model combining B2B contract R&D services for pharmaceutical and biotechnology clients (named customers include Novartis, GSK, Boehringer Ingelheim, Janssen, Menarini, and Alfasigma), catalog sales of recombinant protein research reagents (including SARS-CoV-2 RBD variants), and substantial non-dilutive funding from European, Italian national, and regional grant programs (POR FESR, PNRR, MUR, Horizon Europe, IPCEI Med4Cure). The proprietary pipeline includes Rever3mAb (anti-ErbB3 antibody for reversing oncology therapy resistance), BiTE/FAP bispecific antibodies for rare pediatric cancers, TraZiMab (anti-Aspergillus antibody), and the clinically validated COVID-eVax DNA vaccine candidate.

Takis serves pharmaceutical and biotechnology companies, academic and research institutions (CNR, Sapienza, OPBG), and the broader European public-health ecosystem through consortium-led projects. Its go-to-market is sales-led, driven by direct business development, scientific publication, and consortium-based positioning rather than traditional marketing channels. The company holds ISO 9001:2015 certification and maintains quality management systems aligned with clinical and research-grade standards, supporting its positioning as an integrated European hub for nucleic-acid-based therapy development.

Name

Takis

Legal name

Takis S.r.l.

Website

https://takisbiotech.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Takis is a Rome-based Italian biotechnology company developing proprietary DNA electroporation and X-eVax thermostable vaccine platforms to deliver custom monoclonal antibody generation, recombinant protein production, and gene therapy services to pharmaceutical companies, biotech firms, and academic research institutions across Europe.

Ownership category

akta.pro rank

Product category

Biotechnology Contract Research Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Testing Laboratories (8734)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industry

Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH)

Keywords

• Monoclonal antibody development
• DNA vaccine platform
• Recombinant protein production
• Gene therapy research
• Immunotherapy services

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. R&D Services for Pharmaceutical Companies: Contract research and development services for biotech and pharmaceutical companies, including monoclonal antibody generation, recombinant protein production, and preclinical studies. Services are provided to major pharmaceutical companies (Novartis, GSK, Boehringer Ingelheim) and smaller biotech firms.
2. Recombinant Protein Products: Sale of recombinant proteins including SARS-CoV-2 RBD variants and mutants sold as research reagents for ELISA and Western Blot applications. Products available in catalog format (PR0001-PR0022) with specific concentrations and purity levels.
3. Government and EU Research Grants: Takis participates in multiple funded research projects including IPCEI, Horizon Europe, Italian national and regional programs (POR FESR, PNRR, MUR). Funding supports therapeutic development, vaccine platforms, and infrastructure projects.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Takis is a contract research and biotechnology services company that develops and provides custom monoclonal antibody generation, recombinant protein production, and DNA-based vaccine development services to pharmaceutical, biotech, and academic clients. The company also operates advanced BSL-3 and GMP facilities and develops proprietary therapeutic candidates such as the anti-ErbB3 antibody Rever3mAb and the COVID-eVax DNA vaccine using its proprietary X-eVax electroporation-based platform.

Product overview

Takis is a biotechnology company offering a comprehensive portfolio of research and development services and products in immunotherapy, vaccines, and gene therapy. The core offerings include custom monoclonal antibody generation (mouse monoclonal antibodies, recombinant antibodies, high-throughput production, B-cell isolation), recombinant protein products (SARS-CoV-2 RBD variants), and vaccine development services using the proprietary X-eVax platform with electroporation-based DNA delivery. The company operates advanced facilities including a BSL-3 laboratory, GMP manufacturing facility, and the Rome GeneHub complex for genetic vaccines and monoclonal antibody development. Key pipeline products include Rever3mAb (anti-HER3 antibody for oncology) and COVID-eVax vaccine. The Zetesis Center of Excellence hosts the complete research chain from concept to manufacturing of nucleic acid-based therapies.

Differentiator

Problem solved

Functional benefit

Brands

• X-eVax Platform: An innovative platform enabling rapid vaccine development using fully synthetic DNA technology with electroporation delivery.
• Rever3mAb
• COVID-eVax
• Zetesis
• Rome GeneHub

Products and services

• Mouse Monoclonal Antibodies Custom monoclonal antibody generation service utilizing DNA electroporation immunization and hybridoma technology to deliver mouse monoclonal antibodies with conformational specificity, offered to pharmaceutical, biotech, and academic clients.
• Recombinant Antibodies In vitro antibody production service from supplied VH/VL sequences using mammalian (CHO/293F) and baculovirus expression systems, ensuring long-term supply with minimal batch-to-batch variation for pharmaceutical and biotech clients.
• High Throughput Antibodies Production Large-scale antibody screening and production service delivering 50-100 monoclonal antibodies per project from supplied sequences, with yields up to 500 mg/L and endotoxin levels below 0.1 EU/mg.
• B-cells Isolation and Characterization Microfluidic platform service for isolating and characterizing antigen-specific B cells from various sources, including single-cell PCR amplification, sequencing, and data analysis for downstream recombinant antibody production.
• Recombinant Proteins Catalogue and custom recombinant protein products including SARS-CoV-2 RBD variants expressed in E. coli, insect cells, or HEK293 cells, sold as research reagents for ELISA and Western Blot applications.
• Vaccines & Preclinical Immunology Services Custom plasmid DNA and mRNA manufacturing services using the X-eVax platform with electroporation-based delivery, supporting vaccine development and preclinical immunology studies for pharmaceutical and academic clients.
• Predictive Models Preclinical service offering validated mouse tumor models and humanized mouse models to support immunotherapy and therapeutic antibody development for research and pharmaceutical clients.
• X-eVax Platform Proprietary vaccine development platform using fully synthetic DNA with electroporation delivery, enabling rapid vaccine development with thermostable DNA that does not require cold-chain storage.
• Rever3mAb (Anti-ErbB3 Monoclonal Antibody) Proprietary monoclonal antibody targeting ErbB3 (HER3) to block tumor cell proliferation and revert resistance to conventional oncology therapies, in development for melanoma and non-small cell lung cancer.
• COVID-eVax (COVID-19 Vaccine Candidate) DNA-based COVID-19 vaccine candidate developed on the X-eVax platform; Phase 1 clinical study demonstrated positive immunogenicity and potent T cell immune response induction.

Quantifiable outcome

• Production of 10-20 monoclonal antibodies per year for various clients including major pharmaceutical companies
• +2 more outcomes

Named customers14 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

23 partnerships are on record, tiered core, minor and flagship.

• Menarini BiotechcoreStrategic or Co-development PartnerCollaboration on HERCART project for development of HER2/HER3 antibodies and CAR-T therapies for solid tumors. Menarini responsible for production of anti-HER2 antibody and industrial-scale manufacturing. Also partners on TraZiMab and MenHub projects.
• IRCCS Ospedale Pediatrico Bambino Gesù (OPBG)coreStrategic or Co-development PartnerMultiple collaborations including HERCART (CAR-T generation), TraZiMab (CAR-T for aspergillosis), CARSA (CAR HER3 for sarcoma), HuMAD (humanized mouse models), and GEMMA (CAR T and BiTE for tumor microenvironment). Major pediatric research hospital partner.
• Sapienza Università di RomacoreStrategic or Co-development PartnerPartner in HERCART project for development of companion diagnostics for circulating tumor cells and patient identification for HER2/HER3 targeted therapies.
• IBI-Lorenzini (Istituto Biochimico Lorenzini)coreStrategic or Co-development PartnerCollaboration on REVER3MAB project for industrial-scale manufacturing of anti-ErbB3 antibody under GMP conditions. IBI developing production cell line and upstream/downstream process optimization for clinical trials.
• Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena (IFO-IRE)coreStrategic or Co-development PartnerPartner in REVER3MAB project providing immunohistochemistry, cell biology, immunological monitoring, and DNA sequencing capabilities. Creating biobank of tumor samples and patient lymphocytes for ImmunoAvatar models.
• Dompé FarmaceuticicoreStrategic or Co-development PartnerLead proponent of TREATED project for new therapeutic targets for rare eye diseases. Takis developing BiTE/FAP and BiTE/ErbB3 bispecific antibodies for uveal melanoma and rhabdomiosarcoma treatment.
• Plaisant SrlcoreStrategic or Co-development PartnerPartner in multiple projects including HuMAD (humanized mouse models), CARSA (HER3-CAR for sarcoma), TraZiMab (CAR-T for aspergillosis), and GEMMA (CAR T for NSCLC). Provides in vivo animal modeling capabilities.
• ReiThera SrlcoreStrategic or Co-development PartnerCollaboration on VECTOPUR project for development of production and purification protocols for clinical-grade viral expression vectors (adenovirus, AAV, MVA, HSV) and naked DNA.
• Università degli Studi di Napoli Federico IIcoreStrategic or Co-development PartnerAcademic partner in VECTOPUR project specializing in viral vector development for gene therapy. Part of consortium with ReiThera and Takis for GMP vector production protocols.
• IGEAcoreTechnology or IntegrationCollaboration on GET-NEO project for gene-electro transfer of neoepitopes. IGEA developing electrodes and optimization procedures for electroporation of genetic material into skin, subcutaneous, and muscle tissue.
• CNR (Consiglio Nazionale delle Ricerche)minorStrategic or Co-development PartnerPartner in ITHACA project for high-throughput microfluidic screening of monoclonal antibodies for antitumor therapies.
• Università Campus Biomedico di RomaminorStrategic or Co-development PartnerPartner in ITHACA project and FIDIA project for DNA vaccine manufacturing. Contributing to microfluidic antibody screening platform and PCR robotization.
• BIOGEM ScarlminorStrategic or Co-development PartnerPartner in FIDIA project for Italian DNA factory for applied immunotherapy. Regional biotech company contributing to genetic vaccine development.
• Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori (IRST)minorStrategic or Co-development PartnerPartner in FIDIA project contributing to clinical studies in oncology using genetic vaccines.
• T.E.CO sr.l.minorStrategic or Co-development PartnerPartner in FIDIA project for Italian DNA factory for applied immunotherapy.
• Menarini SpAcoreStrategic or Co-development PartnerCollaboration on MenHub project for creation of industrial biotech hub using DEPArray technology for single-cell separation and CHO cell line development for biopharmaceutical production.
• Menarini BiotechcoreStrategic or Co-development PartnerPartner in GEMMA project for CAR T and BiTE development to convert hostile tumor microenvironment. Contributing to BiTE production scale-up processes.
• Istituto Nazionale Tumori Fondazione G. PascalecoreStrategic or Co-development PartnerLead proponent of Campania Oncoterapie project for drug resistance in tumors. Takis developing cancer vaccines based on tumor antigen engineering and DNA plasmid electroporation.
• Fondazione TelethoncoreStrategic or Co-development PartnerPartner in Dalla Genomica alla Terapia di Tumori Rari project for genomic approach to rare tumor therapy. Takis developing monoclonal antibodies against molecular targets in rare cancers.
• Nouscom srlminorStrategic or Co-development PartnerPartner in Dalla Genomica alla Terapia di Tumori Rari project for genomic characterization and therapy development for rare tumors.
• CatalentcoreStrategic or Co-development PartnerCo-leading Flagship Project 7 (FP7) of Rome Technopole for advanced and automated innovation labs for diagnostic and therapeutic biopharma solutions. Joint development of monoclonal antibodies and biopharma innovations.
• ENEAminorStrategic or Co-development PartnerPartner in Rome Technopole project (Spoke 6) developing bioinformatics pipeline for monoclonal antibody development using ENEA technologies.
• IPCEI Med4Cure NetworkflagshipStrategic or Co-development PartnerZetesis X-eVax project recognized as part of IPCEI (Important Project of Common European Interest) representing strategic European health security investment. Hosts entire research chain from idea to manufacturing of nucleic acid-based therapies in Europe.

Scale indicators17 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• GenScript ProBio: GenScript is a global CRO/CDMO offering gene synthesis, recombinant protein production, and custom monoclonal antibody generation services — directly overlapping Takis's mAb, recombinant protein, and cell-line development offerings. Comparable in customer base (pharma and biotech) and technology scope (CHO/293 expression, antibody discovery).
• AbCellera Biologics: AbCellera operates a leading antibody discovery platform using single-cell B-cell screening and microfluidic technology to generate therapeutic mAbs for pharma partners. Directly comparable to Takis's B-cell isolation and characterization platform and high-throughput antibody production service.
• Evotec SE: Evotec is a Germany-based contract research organization providing antibody discovery, protein production, and integrated drug discovery services to pharma and biotech. Comparable B2B R&D services business model with similar end-to-end offering spanning antibody generation through preclinical development.
• Twist Bioscience: Twist provides synthetic DNA and antibody discovery services using high-throughput silicon-based DNA synthesis — analogous to Takis's synthetic DNA and X-eVax platform technology. Both serve pharma/biotech with custom biologics discovery tools.
• IRBM S.p.A. IRBM is an Italian biotech CRO/CDMO offering integrated drug discovery and GMP manufacturing for biologics and vaccines, based near Rome. Closest geographic and operational peer to Takis, with overlapping enterprise pharma client relationships and similar BSL/GMP infrastructure.

Broad incumbents

• Charles River Laboratories: Charles River is a global CRO/CDMO providing antibody discovery, recombinant protein production, and preclinical services across pharma and academia. Larger-scale incumbent offering the same core services as Takis with broader geographic reach and deeper commercial relationships.
• Catalent, Inc. Catalent is a global CDMO providing biologics development, GMP manufacturing, and clinical supply services. Takis is an active partner with Catalent in Rome Technopole Flagship Project 7, and Catalent serves overlapping enterprise pharma customers for biologics and gene therapy manufacturing.
• BioNTech SE: BioNTech is a leading mRNA and nucleic acid immunotherapy company developing cancer vaccines and infectious disease vaccines. Comparable DNA/RNA vaccine platform to Takis's X-eVax, with broader commercial-stage validation and COVID vaccine franchise scale.

Emerging players

• Nouscom Srl: Nouscom is an Italian biotech developing personalized neoantigen cancer vaccines using viral vectors and synthetic DNA — directly comparable to Takis's GET-NEO (gene electro-transfer of neoepitopes) and X-eVax personalized cancer vaccine programs. Active consortium partner with Takis in Dalla Genomica alla Terapia di Tumori Rari.
• ReiThera Srl: ReiThera is an Italian biotech developing viral vector vaccines and gene therapies, with GMP manufacturing capacity. Active Takis partner in VECTOPUR (viral vector production) and customer for mAb services — closely comparable in scale, geography, and viral vector/DNA technology focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@infotakischannel2929
• Facebookfacebook.com/Takisbiotech
• LinkedInlinkedin.com/company/takis

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Takis